Bicara Therapeutics Inc. Common Stock (BCAX) NASDAQ
22.58
-0.51(-2.21%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
22.58
-0.51(-2.21%)
Currency In USD
Address
116 Huntington Avenue
Boston, MA 02116
United States of America (the)
Phone
617-468-4219
Website
Sector
Healthcare
Industry
Biotechnology
Employees
55
First IPO Date
September 13, 2024
| Name | Title | Pay | Year Born |
| Claire Mazumdar Clemon | Chief Executive Officer & Director | 927,688 | 1990 |
| David Raben | Chief Medical Officer | 709,164 | 1964 |
| Ryan Cohlhepp | President, Chief Operating Officer & Director | 858,400 | 1977 |
| Ivan Hyep | CFO & Treasurer | 915,375 | 1985 |
| Pauline Dufresne | Chief People Officer | 0 | N/A |
| Tanya Green | Chief Development Officer | 0 | N/A |
| Lara S. Meisner | Chief Legal Officer, Compliance Officer & Corporate Secretary | 0 | 1972 |
| Jean-Paul Rodrique | Senior Vice President & Global Head of Quality Assurance | 0 | N/A |
| Jenna Cohen | Chief Corporate Affairs Officer | 0 | N/A |
| Rachel Salazar | SVP of R&D Strategy and Operations | 0 | N/A |
| Sathish Hasige | Senior Vice President and Head of Technical Operations & Supply Chain | 0 | N/A |
| Jeltje Schulten | Senior Vice President of Clinical & Medical Affairs | 0 | N/A |
| Angela Windt | Vice President & Head of Regulatory Affairs | 0 | N/A |
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.